Under this licensing deal, Hetero will be supplying Remdesivir in 127 countries, including India, subject to regulatory approvals in respective countries.
Remdesivir will be manufactured in our formulation facility in Hyderabad, India, which has been approved by stringent global regulatory authorities such as USFDA and EU, among others.
Hetero has developed the fully vertically integrated supply chain for this product complementing the "Make in India" campaign as defined by our Hon'ble Prime Minister.
US Food and Drug Administration (FDA) has granted emergency use authorization for the investigational antiviral Remdesivir to treat COVID-19. Remdesivir is authorized for the treatment of hospitalised patients with severe COVID-19 disease.
The optimal duration of treatment is still being studied in ongoing clinical trials. Under the EUA, both 5-day and 10-day treatment durations are suggested, based on the severity of disease.
The authorization is temporary and does not take the place of the formal new drug application submission, review and approval process. The EUA allows for the distribution and emergency use of Remdesivir only for the treatment of COVID-19; Remdesivir remains an investigational drug and is not approved anywhere globally including US and India.
Hetero is one of India's largest generic pharmaceutical companies and the world's largest producer of anti-retroviral drugs. With 25 years of expertise in the pharmaceutical industry, Hetero's strategic business areas spread across APIs, generics, biosimilars, custom pharmaceutical services and branded generics.
Hetero has 36 state-of-the-art manufacturing facilities, 300 plus products in its portfolio and has a strong global presence in over 126 countries.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling